- Class Actions
- Commercial Litigation
- Defective Products
- Drug Injury
- Personal Injury
- Securities Fraud
- Toxic Exposure
- Whistleblower Claims
- Ocella, Yasmin, Yaz
- Sleeping Pills
- Da Vinci Robot
- DePuy Hip Recall
- Stryker Recall
- Stryker Lawsuit
- Transvaginal Mesh
- Zimmer Hip Implant
- Aveeno Lawsuit
- Atlas Roofing Lawsuit
- Avon/Clarins Products
- AZEK Decking
- Chinese Drywall
- Chrysler Lock-Ups
- Demilec Insulation
- Electrolux Lawsuit
- Energy Drink Lawsuit
- Flushmate Systems
- Ford 5.4L Engine
- Ford & Mercury Transmissions
- Ford Mileage Claims
- GAF Decking
- Jeld-Wen Low E
- LP/ABTCO TrimBoard
- Norcold Lawsuit
- Pozzi and Jeld-Wen
- Remington Lawsuit
- TimberTech Decking
- Toyota Power Windows
- Trex Decking Lawsuit
Category : Pharmaceutical Injury
Last week, the Washington Post reported the story of a Washington state couple suing Tylenol manufacturers, Johnson & Johnson. According to the Post, Daniel and Katy Moore claim that their 2-year-old son River Moore died as a result of consuming a Children’s Tylenol product. The specific package in question had been recalled due to high levels of the active ingredient acetaminophen. Shortly after taking the over-the-counter medication for a slight fever, the young boy died of liver failure, a known effect of an acetaminophen overdose. “The lawsuit, filed…in Philadelphia’s Court of Common Pleas, accuses Johnson & Johnson of recklessness, negligence, breach of warranty, infliction of emotional distress, conspiracy and other offenses,” the story explains.
The article also notes that Johnson & Johnson’s 2009 recall of the product at the center of this lawsuit is “part of the company’s continuing string of recalls of drugs and medical devices.” In fact, the drug injury practice of Seeger Weiss LLP is currently investigating complaints of liver damage at the hands of Tylenol. If you or someone you know has suffered liver damage as a result of taking Tylenol, let Seeger Weiss help you seek justice. Our experienced drug injury attorneys have won billions of dollars for our clients and will review your Tylenol liver damage case for free.
Sports media outlets have been abuzz since the Associated Press published the results of an interview with 44 National Football League players on Sunday that seemed to confirm the existence of a league-wide “tough-it-out” attitude. The group of interviewees included at least one representative from each of the 32 teams, 33 starters, 11 reserves, 25 offensive players, and 19 defensive players. Among the questions posed, one asked, “If you get what you think could be a concussion, do you think you would hide it and try to stay in the game or immediately pull yourself out?” 23 of the 44 players admitted that they would attempt to hide their injuries.
While the results of the survey are disturbing, they should not come as a shock to anyone following the recent case against the NFL that Seeger Weiss LLP has brought on behalf of 11 former players. The plaintiffs allege that they were regularly administered the drug Toradol, which can mask the symptoms of a concussion and cause cerebral bleeding. The case, and many others like it, have brought to light a brutal culture in the NFL, in which potentially life-threatening conditions are often left untreated. Another question in the AP’s interview asked if players believed an independent neurologist should be present at games to check for concussions. 31 of the 44 players answered “Yes.”
To learn more about Seeger Weiss’ investigation of the NFL’s use of Toradol, click here.
To read the full results of the Associated Press interview, click here.
A recent health report from CBS Philadelphia investigates DePuy Orthopaedics’ defective hip replacements, and asks, “Why were so many people being injured by implants that are FDA approved?” The hip implants, which due to their design have been shown to lead to blood poisoning, were recalled in August 2010. Before they were however, they caused many of the patients who received them life-threatening conditions, toxic injuries and debilitating pain. Visit CBS Philadelphia to watch a video featuring two of these stories and read the entire report.
Seeger Weiss LLP is currently investigating the claims of those harmed by the DePuy ASR Hip Implant. If you or someone you know has suffered complications from the DePuy ASR Hip Implant, contact Seeger Weiss LLP today. An attorney with our award-winning drug injury class action practice will assist you in evaluating your claim. Attorney consultations incur no obligation on your part and all initial consultations are free of charge. Seeger Weiss LLP has office locations in New York, New Jersey, Pennsylvania and California.
A study published in the British Journal of Pharmacology last week confirmed that acetaminophen, the active ingredient in Tylenol, can cause potentially fatal side effects. As USA Today reports, “Taking slightly too much of the pain reliever acetaminophen…over time can lead to an overdose that can cause liver failure and death…”
The experienced drug injury practice of Seeger Weiss LLP investigates claims of liver damage caused by acetaminophen. If you or someone you know has taken a drug containing acetaminophen and suffered liver damage or failure, contact us today. An experienced drug injury attorney with Seeger Weiss LLP will assist you in evaluating your claim. Attorney consultations incur no obligation on your part and all initial consultations are free of charge. Seeger Weiss LLP has office locations in New York, New Jersey, Philadelphia and California.
As lawsuits against Fosamax manufacturer, Merck & Co. emerge around the country, drug injury experts are warning patients and doctors about the drug’s harmful side effects. Most notably, the medication, which is indicated to strengthen the bones of those at risk for osteoporosis, has actually been said to make bones weaker, causing an array of unusual problems. Because of such claims, the FDA is expected to publish official warnings about Fosamax later this month. Sheryl Vondracek, an associate professor at the University of Colorado’s Department of Clinical Pharmacy cited in this article, notes that “osteoporosis of the jaw…has been reported with longer term use and atypical fractures, which are fractures of the femur, or thigh bone.”
Reports surfaced early today that profits for Japan-based Takeda Pharmaceutical Co. have substantially declined. One factor that several news sources, including Bloomberg Businessweek, have attributed to the company’s losses is the controversy surrounding its top-selling drug, Actos. Calls for the FDA to release cautionary warnings for the diabetes medication began to emerge after it was linked to an increased risk of bladder cancer. Takeda projects that its net income will plunge by over 30 percent over the course of the next four months.
Following negative media attention and a swarm of recent pharmaceutical drug litigation involving the medication, the European Commission has requested that the European Medicines Agency (EMA) clarify its position on the use of Actos. Both France and Germany prohibited the diabetes drug after reports indicated that it increased patients’ risk of heart attack and bladder cancer. Although the FDA did not officially ban Actos in the U.S., it added warnings to its label. Now, the EMA has asserted that while the drug can be a “valid treatment” for type 2 diabetes, it should only be prescribed when other medications have failed. Furthermore, the agency urges doctors who prescribe Actos to closely monitor their patients. Read the full story.
The experienced pharmaceutical injury attorneys in Seeger Weiss’ drug injury practice are closely following developments about reported Actos side effects. To learn more, visit our Actos Investigation Page.
Blood clots are a well-known risk of taking birth control pills. Now the FDA is investigating oral contraceptives that contain drospirenone, such as Yaz and Yasmin, after new research suggests that these pills increase the risk of blood clots above that of other oral contraceptives.
Most birth control pills combine estrogen with another female sex hormone, progestin. In two studies published in the British Medical Journal in April, pills containing drospirenone, a type of progestin, were found to carry a two- to three-fold higher risk of venous thromboembolism, or a blood clot in a deep vein, than pills containing a different progestin, levonorgestrel.
The FDA said it was “aware of two newly published studies” that found what appeared to be an increased risk for venous thromboembolism (VTE)—blood clots— in women taking birth control pills containing the synthetic version of the hormone progestin called drospirenone. Older birth control pills tend to contain a version of progestin called levonorgestrel.
“This risk is reported to be up to two to three times greater than the risk of VTE associated with using levonorgestrel-containing pills,” the FDA said.
Among the pills containing drospirenone are Yaz, which is sold generically as Gianvi and Loryna; Yasmin, which is sold generically as Ocella, Syeda and Zarah; and Beyaz and Safyral.
Partners Chris Seeger and Dave Buchanan, along with Mike Papantonio of Levin Papantonio Thomas Mitchell Rafferty & Proctor, will be heading up a forum on Fosamax-induced femur fractures litigation in Miami on June 24, 2011. The details are below:
Fosamax-Induced Femur Fractures Litigation
presented by Mass Torts Made Perfect, a plaintiffs’
only forum on these two emerging mass torts
Friday, June 24, 2011
Loews Miami Beach Hotel – Miami, Florida
Topics to Include:
- The Science of Oversupression of Bone Turnover
- Epidemiology of Fosamax and Atypical Femur Fractures
- The Relationship Between ONJ and Atypical Fremur Fractures
- State of Litigation: New Jersey, Florida, California State Courts
- The Femur MDL Update
- Moving the Liability Case Forward: What Work Product Exists?
- Understanding Damages
- Case Selection Criteria
Presented by: Levin Papantonio Thomas Mitchell Rafferty & Proctor, PA, Pensacola, FL
Price: $795 for attorneys and $595 for paralegals.
To register, call Sharon Boothe at 610-644-3943, or email firstname.lastname@example.org.
Sponsorship and exhibitor information available by contacting Sharon Boothe. A small block of rooms has been reserved at the hotel at the discounted room rate of $179.00. Call the hotel directly at 305-604-1601, or toll free at 1-877-563-9762. Refer to the “Mass Torts Made Perfect” program to get the discounted room rate. The room rate is available also three days prior and three days after the conference, if you decide to extend your stay. Please direct any questions to Sharon Boothe, at 610-644-3943.